Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Duration of Treatment for Low-Risk PD-Related Peritonitis
NCT03675854Phase 4Withdrawn
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefazolin in peritonitis (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Complete cure of the peritonitis episode at 6 months. Planned start Jan 2019; status: withdrawn.
02
Drugs
cefazolin
03
Conditions
peritonitis
Beyond the preview
Go deeper on NCT03675854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675854.